AMAG AMAG Pharmaceuticals, Inc.

18.10
-0.40  -2%
Previous Close 18.50
Open 18.50
Price To book 0.69
Market Cap 634.31M
Shares 35,045,000
Volume 1,954,923
Short Ratio 7.22
Av. Daily Volume 1,189,150

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Rekynda
Hypoactive sexual desire disorder (HSDD)
Phase 3 trial to be completed estimated 1H 2017. sNDA due mid 2017.
Feraheme
Adults with iron deficiency anemia (IDA)
sNDA filing announced April 17, 2017. PDUFA date estimated October 17, 2017 assuming 6-month priority review.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs
  2. Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
  3. AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy
  4. Bear of the Day: AMAG Pharmaceuticals (AMAG)
  5. AMAG Pharmaceuticals, Inc. -- Moody's upgrades AMAG's sr. notes to Ba3; affirms B2 CFR
  6. What Makes AMAG Pharmaceuticals (AMAG) a Strong Sell?
  7. AMAG Pharmaceuticals to Host Analyst Day on May 24th in New York
  8. ETFs with exposure to AMAG Pharmaceuticals, Inc. : May 5, 2017
  9. AMAG Pharmaceuticals Announces Pricing of $300 Million of 3.25% Convertible Senior Notes Due 2022
  10. AMAG Pharmaceuticals, Inc. -- Moody's: AMAG's proposed refinancing credit positive
  11. Edited Transcript of AMAG earnings conference call or presentation 2-May-17 12:00pm GMT
  12. AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
  13. AMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due 2022
  14. AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y
  15. Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals
  16. AMAG Pharmaceuticals reports 1Q loss
  17. AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
  18. AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study
  19. Investor Network: AMAG Pharmaceuticals, Inc. to Host Earnings Call
  20. AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference